Analysts Issue Forecasts for Curis FY2026 Earnings

Curis, Inc. (NASDAQ:CRIS) – Analysts at Cantor Fitzgerald issued their FY2026 EPS estimates for shares of Curis in a report released on Monday, June 9th. Cantor Fitzgerald analyst L. Watsek expects that the biotechnology company will post earnings of ($1.71) per share for the year. The consensus estimate for Curis’ current full-year earnings is ($7.12) per share.

A number of other analysts also recently commented on the company. Wall Street Zen began coverage on Curis in a research note on Friday, May 16th. They issued a “hold” rating on the stock. HC Wainwright reissued a “buy” rating and issued a $17.00 price objective on shares of Curis in a research note on Monday, May 19th.

Curis Stock Performance

CRIS opened at $2.77 on Wednesday. Curis has a one year low of $1.02 and a one year high of $8.83. The stock’s fifty day moving average is $1.88 and its 200-day moving average is $2.74. The company has a market capitalization of $28.98 million, a PE ratio of -0.35 and a beta of 3.69.

Curis (NASDAQ:CRIS) last posted its quarterly earnings data on Tuesday, May 6th. The biotechnology company reported ($1.25) EPS for the quarter, missing analysts’ consensus estimates of ($1.14) by ($0.11). Curis had a negative return on equity of 923.37% and a negative net margin of 443.35%. The firm had revenue of $2.38 million during the quarter, compared to the consensus estimate of $2.37 million. During the same period in the prior year, the firm posted ($2.05) EPS.

Institutional Investors Weigh In On Curis

A number of institutional investors and hedge funds have recently modified their holdings of CRIS. Squarepoint Ops LLC acquired a new stake in shares of Curis during the fourth quarter worth $35,000. Millennium Management LLC raised its position in shares of Curis by 92.6% during the fourth quarter. Millennium Management LLC now owns 25,557 shares of the biotechnology company’s stock worth $78,000 after purchasing an additional 12,287 shares during the period. XTX Topco Ltd acquired a new stake in shares of Curis during the first quarter worth $27,000. Geode Capital Management LLC raised its position in shares of Curis by 27.3% during the fourth quarter. Geode Capital Management LLC now owns 83,129 shares of the biotechnology company’s stock worth $254,000 after purchasing an additional 17,820 shares during the period. Finally, CM Management LLC raised its position in shares of Curis by 9.1% during the first quarter. CM Management LLC now owns 240,000 shares of the biotechnology company’s stock worth $504,000 after purchasing an additional 20,000 shares during the period. 29.97% of the stock is owned by institutional investors and hedge funds.

About Curis

Curis, Inc, a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes.